Prostate Cancer - Featured Clinical Trials
The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:
- Enhancing Cancer Information Materials with Multimedia
(Posted: 02/10/2009) - Patients with newly diagnosed prostate or breast cancer or who are finishing or recently completed breast cancer treatment and who call the NCI's Cancer Information Service for information will be invited to participate in a trial of multimedia information during the call.
- Targeting Occult Cancer Cells in High-risk Prostate Cancer Patients
(Posted: 09/09/2008) - In this trial, prostate cancer patients classified as having a high risk of recurrence will be randomly assigned to undergo a course of neoadjuvant therapy consisting of chemotherapy and anti-androgen therapy or proceed directly to surgery.
- Cilengitide for PSA-Only Progressive Prostate Cancer
(Posted: 03/27/2007, Updated: 06/17/2008) - In this trial, men with prostate cancer that is progressing, as indicated by a rising PSA level, despite antiandrogen therapy will be treated with a drug called cilengitide, which blocks receptor proteins that help prostate cancer grow and spread.
- Cediranib for Androgen-Independent Prostate Cancer
(Posted: 04/29/2008) - In this trial, men with metastatic, androgen-independent prostate cancer whose cancer has continued to progress on docetaxel will take oral cediranib daily.
- Bevacizumab for Hormone-Refractory Prostate Cancer
(Posted: 09/05/2006, Updated: 12/26/2007) - In this trial, men with hormone-refractory prostate cancer that has spread (metastasized) will receive standard chemotherapy with the drugs docetaxel and prednisone. Half of the participants will be randomly assigned to additionally receive treatment with a monoclonal antibody called bevacizumab.